“…Inbred B6 and CD45.1 + congenic B6 (B6.SJL- Ptprc a
Pep3 b /BoyJ) mice, TCRβ-transgenic EF4.1 mice (Antunes et al., 2008), TCRαβ doubly transgenic EVα2 mice (Merkenschlager et al., 2016), Rag1-deficient ( Rag1 −/− ) mice (Mombaerts et al., 1992), B cell-receptor-deficient ( Ighm −/− ) mice (Kitamura et al., 1991), mice with an activatable YFP gene targeted into the Gt(ROSA)26Sor ( R26 ) locus (Srinivas et al., 2001), mice with a targeted insertion of Cre recombinase into the Tnfrsf4 locus (Klinger et al., 2009) ( Tnfrsf4 Cre ), mice with a conditional Bcl6 allele (Kaji et al., 2012) ( Bcl6 fl ), endogenous ecotropic murine-leukemia-virus-deficient ( Emv2 −/− ) mice (Young et al., 2012), mice with a targeted insertion of GFP into the Prdm1 locus (Kallies et al., 2009) (Blimp1-GPF), and mice with a targeted insertion of tdTomato fluorescent protein into the Gzmb locus (Mouchacca et al., 2013) (GzmB-tdTomato) were all on the B6 genetic background and were maintained at the Francis Crick Institute’s animal facilities. All animal experiments were approved by the ethical committee of the Francis Crick Institute and were conducted according to local guidelines and UK Home Office regulations under the Animals (Scientific Procedures Act) 1986 (ASPA).…”